PL3250202T3 - Kompozycja do zastosowania w zwiększaniu skuteczności wszczepiania hematopoetycznych komórek macierzystych po transplantacji - Google Patents

Kompozycja do zastosowania w zwiększaniu skuteczności wszczepiania hematopoetycznych komórek macierzystych po transplantacji

Info

Publication number
PL3250202T3
PL3250202T3 PL16701770T PL16701770T PL3250202T3 PL 3250202 T3 PL3250202 T3 PL 3250202T3 PL 16701770 T PL16701770 T PL 16701770T PL 16701770 T PL16701770 T PL 16701770T PL 3250202 T3 PL3250202 T3 PL 3250202T3
Authority
PL
Poland
Prior art keywords
transplantation
composition
stem cells
haematopoetic stem
increasing engraftment
Prior art date
Application number
PL16701770T
Other languages
English (en)
Inventor
Michael Freissmuth
Eva-Maria ZEBEDIN-BRANDL
Zahra KAZEMI
Original Assignee
SciPharm S.à r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SciPharm S.à r.l. filed Critical SciPharm S.à r.l.
Publication of PL3250202T3 publication Critical patent/PL3250202T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669Bone marrow stromal cells; Whole bone marrow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/73Hydrolases (EC 3.)
    • C12N2501/734Proteases (EC 3.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16701770T 2015-01-27 2016-01-27 Kompozycja do zastosowania w zwiększaniu skuteczności wszczepiania hematopoetycznych komórek macierzystych po transplantacji PL3250202T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152664 2015-01-27
EP16701770.6A EP3250202B1 (en) 2015-01-27 2016-01-27 Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
PCT/EP2016/051672 WO2016120310A1 (en) 2015-01-27 2016-01-27 Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation

Publications (1)

Publication Number Publication Date
PL3250202T3 true PL3250202T3 (pl) 2021-08-30

Family

ID=52449965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16701770T PL3250202T3 (pl) 2015-01-27 2016-01-27 Kompozycja do zastosowania w zwiększaniu skuteczności wszczepiania hematopoetycznych komórek macierzystych po transplantacji

Country Status (25)

Country Link
US (1) US10226465B2 (pl)
EP (1) EP3250202B1 (pl)
JP (1) JP6669762B2 (pl)
KR (1) KR102577669B1 (pl)
CN (1) CN107548305A (pl)
AU (1) AU2016212090B2 (pl)
BR (1) BR112017016077A2 (pl)
CA (1) CA2973146C (pl)
CL (1) CL2017001903A1 (pl)
CY (1) CY1124317T1 (pl)
DK (1) DK3250202T3 (pl)
EA (1) EA039149B1 (pl)
ES (1) ES2872698T3 (pl)
HR (1) HRP20210930T1 (pl)
HU (1) HUE054615T2 (pl)
IL (1) IL253389B (pl)
LT (1) LT3250202T (pl)
PL (1) PL3250202T3 (pl)
PT (1) PT3250202T (pl)
RS (1) RS61945B1 (pl)
SG (1) SG11201705812SA (pl)
SI (1) SI3250202T1 (pl)
SM (1) SMT202100465T1 (pl)
UA (1) UA122488C2 (pl)
WO (1) WO2016120310A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507515YA (en) 2013-03-15 2015-10-29 Marcus Kare Torleif Larsson Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
WO2018073615A1 (en) * 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP4196260A4 (en) * 2020-08-14 2025-04-30 Navan Technologies, Inc. METHODS AND APPARATUS FOR DELIVERING BIOMOLECULES TO PRIMARY HUMAN HEMATOPOIETIC STEM CELLS USING NANOSTRAWS
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
CN112961827B (zh) * 2021-04-25 2024-04-26 河南省肿瘤医院 佛司可林在t细胞培养中的应用
WO2025172541A1 (en) 2024-02-15 2025-08-21 Aop Orphan Pharmaceuticals Gmbh New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
CA2623826A1 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
AU2008210988B2 (en) * 2007-02-01 2012-09-06 Allocure, Inc. Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
WO2009152186A1 (en) * 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
WO2012074676A2 (en) 2010-11-09 2012-06-07 Emory University Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto
US10213464B2 (en) * 2011-01-13 2019-02-26 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US20140288010A1 (en) * 2013-02-22 2014-09-25 Georgia Regents Research Institute, Inc. Compositions and Methods for Increasing Stem Cell Survival

Also Published As

Publication number Publication date
IL253389B (en) 2021-02-28
KR102577669B1 (ko) 2023-09-12
HUE054615T2 (hu) 2021-09-28
EP3250202B1 (en) 2021-03-10
EA201791703A1 (ru) 2017-11-30
DK3250202T3 (da) 2021-05-31
RS61945B1 (sr) 2021-07-30
KR20170106980A (ko) 2017-09-22
HRP20210930T1 (hr) 2021-09-03
JP6669762B2 (ja) 2020-03-18
EP3250202A1 (en) 2017-12-06
ES2872698T3 (es) 2021-11-02
US10226465B2 (en) 2019-03-12
CY1124317T1 (el) 2022-07-22
SG11201705812SA (en) 2017-08-30
WO2016120310A1 (en) 2016-08-04
UA122488C2 (uk) 2020-11-25
CA2973146C (en) 2024-01-09
SMT202100465T1 (it) 2021-09-14
BR112017016077A2 (pt) 2018-04-03
SI3250202T1 (sl) 2021-07-30
CN107548305A (zh) 2018-01-05
CA2973146A1 (en) 2016-08-04
EA039149B1 (ru) 2021-12-10
AU2016212090A1 (en) 2017-08-03
LT3250202T (lt) 2021-06-25
IL253389A0 (en) 2017-09-28
CL2017001903A1 (es) 2018-03-23
US20180008606A1 (en) 2018-01-11
AU2016212090B2 (en) 2021-05-20
PT3250202T (pt) 2021-06-17
JP2018505171A (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
IL253389B (en) The composition for use in increasing the assembly efficiency of "haematopoietic" stem cells after transplantation
EP3331582A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
IL250689B (en) Rearrangement of multipurpose stem cells
EP3019596A4 (en) Compositions and methods for reprograming non- pluripotent cells into pluripotent stem cells
IL251951A0 (en) Methods and compositions for natural killer cells
EP3230460A4 (en) Methods and compositions for selectively eliminating cells of interest
SG10201706858XA (en) Methods and compositions for mobilizing stem cells
SG11201610699XA (en) Manufacture and cryopreservation of fucosylated cells for therapeutic use
SG11201607925SA (en) Improved stem cell composition
EP3177144A4 (en) Compositions and methods for selectively depleting senescent cells
IL257678A (en) Methods of stem cell transplantation
PL3157504T3 (pl) Kompozycje stymulujące komórki macierzyste
SG10201913752PA (en) Methods and compositions for stem cell transplantation
EP3162883A4 (en) Jig for vitrification preservation of cells or tissues
IL249376B (en) Proliferation and transplantation of stem cells using notch1 and/or notch2 agonists
PT3795171T (pt) Transferrina para utilização em transplante renal
IL246667B (en) Preparations for the treatment of abnormal cell growth
EP3203835A4 (en) Method and composition for hypothermic storage of placental tissue
EP3139913A4 (en) Methods and compositions for non-cytotoxic stem cell transplantation
EP3178318A4 (en) Composition for promoting storage stability of stem cells
EP3134096A4 (en) Methods of enhancing stem cell engraftment
IL264205A (en) Cellular compounds for tissue regeneration
PL3638021T3 (pl) Sposoby konserwacji komórek
HK1241742A1 (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
GB201403576D0 (en) Alloy composition for electrochemical cell